XtalPi Added to MSCI China Index, Recognized as Global Investment Benchmark for Growth Potential

Blog details
3 min read
Share this:

XtalPi (2228.HK), the AI and robotics-driven platform accelerating drug and new materials innovation, has been selected for inclusion in the prestigious MSCI China Index, one of MSCI’s most closely watched flagship indices.

The inclusion follows MSCI’s November 2025 Semi-Annual Index Review and will become effective after the market closes on November 24, 2025.

  • Global Recognition: Inclusion in the MSCI China Index signifies that XtalPi meets rigorous international standards for market capitalization, representativeness, and liquidity. It grants the stock entry into the broader MSCI Global Standard Index Series, typically attracting substantial passive capital inflows from global institutional investors who widely track the benchmark.
  • Validation of Value: The selection confirms the company’s investment value and growth potential have been recognized by the authoritative global capital market.

XtalPi is a pioneering ‘AI for Science’ platform that deeply integrates quantum physics, Artificial Intelligence, and large-scale standardized experimental robotics.

  • Market Leadership: XtalPi has established partnerships with over 300 international enterprises, innovative companies, and research institutions.
  • Dual AI Capabilities: The company is one of the few AI R&D platforms in the industry that has secured high-value international collaborations in both AI small molecule and AI large molecule (biologics) drug development.
  • Client Base: XtalPi’s client list includes 17 out of the top 20 global pharmaceutical companies.
  • Performance: The company achieved profitability in the first half of 2025, with business spanning pharmaceuticals, energy, agriculture, new materials, and consumer products.

The inclusion in the MSCI China Index serves as a positive affirmation of XtalPi’s performance in the secondary market, strong fundamentals, and promising outlook. The company plans to use this momentum to continue strengthening its core technological innovation capabilities, solidify and accelerate commercialization results, and deliver sustainable long-term returns for investors.

Your next success starts here

Recommended articles

Leading Automation Capabilities of XtalPi Recognized by Global Chemical Giant – Successful Launch of Advanced Automated Workstation at BASF
XtalPi and VISEN Pharmaceuticals Enter Strategic Partnership to Co-Develop Innovative Endocrine Therapies for a Multi-Billion Dollar Market
XtalPi Partners with Mirxes and Signet Therapeutics to Launch Global “AI Screening + Precision Treatment” Closed-Loop System for Gastric Cancer
XtalPi-Powered ReviR Therapeutics Secures Additional NMPA Clinical Approval for “AI+RNA” Rare Disease Pipeline RTX-117

XtalPi Newsletter